Thursday, 20 Sep 2018

You are here

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change. At EULAR 2018 a study of 1776 patients from the VA database showed again the notion that if a patient is in high disease activity, treatment changes are made only half the time (FRI0018). My response to this is that the measures are not reflecting active RA (i.e. scores driven by non-inflammatory pain, tender joints from OA), or the patient refuses to accept more treatment or the most likely is that the score is not being calculated (i.e. for billing reimbursement, the components are collected but scores are not calculated during the visit) as the physician doesn’t think the disease is active (enough) to warrant a treatment change. However, even more strangely, 15% who were in remission had dose increasing or a new drug started and 21 to 25% in low disease activity had increases in treatment. I can say that the disease activity instruments used in the study (DAS28, CDAI and RAPID3) had a ‘dose response’ meaning that the frequency of treatment increases was lowest in remission, and highest in high disease activity and there will never be 100% concordance with outcome measures and treatment changes in clinical practice. It is too bad we don’t have the HbA1C (glycated Hbg) equivalent of RA – one easy test reflecting recent disease activity that we could target.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Treat-to-Target in RA: No Increase in AEs

Implementing a treat-to-target approach for the care of rheumatoid arthritis (RA) did not result in an increase in adverse events or resource use, a post-hoc analysis of a randomized trial showed.

Mediterranean Diet Reduces Risk of Rheumatoid Arthritis

High adherence to a Mediterranean diet appears to be associated with a lower risk of rheumatoid arthritis (RA), especially in men and those who are seropositive, according to a study published in Arthritis Research & Therapy.

Early Exposure to Passive Smoke May Up Risk for RA Later in Life

Exposure to second-hand smoke during childhood was associated with an increased risk for developing rheumatoid arthritis (RA) later in life, researchers said.

Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence

There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself.  There are fewer studies about whether it is safe to use a TNFi in someone with a pre-existing history of cancer.

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).